BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 27471868)

  • 21. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas.
    Blystad AK; Enblad G; Kvaløy S; Berglund A; Delabie J; Holte H; Carlson K; Kvalheim G; Bengtsson M; Hagberg H
    Bone Marrow Transplant; 2001 Apr; 27(7):711-6. PubMed ID: 11360110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
    J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
    Gleeson M; Peckitt C; Cunningham D; Gibb A; Hawkes EA; Back M; Yasar B; Foley K; Lee R; Dash J; Johnson H; O'Hara C; Wotherspoon A; Attygalle A; Menasce L; Shenjere P; Potter M; Ethell ME; Dearden C; Radford J; Chau I; Linton K
    Leuk Lymphoma; 2018 Jul; 59(7):1586-1595. PubMed ID: 29119842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
    Rodríguez J; Conde E; Gutiérrez A; Arranz R; Gandarillas M; Leon A; Ojanguren J; Sureda A; Carrera D; Bendandi M; Moraleda J; Ribera JM; Albo C; Morales A; García JC; Fernández P; Cañigral G; Bergua J; Caballero MD;
    Eur J Haematol; 2007 Apr; 78(4):290-6. PubMed ID: 17378891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.
    Ellin F; Landström J; Jerkeman M; Relander T
    Blood; 2014 Sep; 124(10):1570-7. PubMed ID: 25006130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission.
    Mehta N; Maragulia JC; Moskowitz A; Hamlin PA; Lunning MA; Moskowitz CH; Zelenetz A; Matasar MJ; Sauter C; Goldberg J; Horwitz SM
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):664-70. PubMed ID: 24035712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma.
    Corradini P; Vitolo U; Rambaldi A; Miceli R; Patriarca F; Gallamini A; Olivieri A; Benedetti F; Todeschini G; Rossi G; Salvi F; Bruno B; Baldini L; Ferreri A; Patti C; Tarella C; Pileri S; Dodero A
    Leukemia; 2014 Sep; 28(9):1885-91. PubMed ID: 24662801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
    Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
    Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
    Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
    Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.
    Schmitz N; de Leval L
    Br J Haematol; 2017 Mar; 176(6):851-866. PubMed ID: 27982416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.
    Verdonck LF; van Putten WL; Hagenbeek A; Schouten HC; Sonneveld P; van Imhoff GW; Kluin-Nelemans HC; Raemaekers JM; van Oers RH; Haak HL
    N Engl J Med; 1995 Apr; 332(16):1045-51. PubMed ID: 7898521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.
    Chen AI; McMillan A; Negrin RS; Horning SJ; Laport GG
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):741-7. PubMed ID: 18541192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes of post-remission therapy using (90)yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma.
    Han EJ; Lee SE; Kim SH; Sohn HS; Jung SE; Park G; Choi BO; Lee SN; Yang SW; Han K; Cho SG
    Ann Hematol; 2011 Sep; 90(9):1075-82. PubMed ID: 21336624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
    Mamez AC; Dupont A; Blaise D; Chevallier P; Forcade E; Ceballos P; Mohty M; Suarez F; Beguin Y; Peffault De Latour R; Rubio MT; Tournilhac O; Nguyen S
    J Hematol Oncol; 2020 May; 13(1):56. PubMed ID: 32429979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation.
    Kahl C; Leithäuser M; Wolff D; Steiner B; Hartung G; Casper J; Freund M
    Ann Hematol; 2002 Nov; 81(11):646-50. PubMed ID: 12454703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
    Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
    Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment.
    Mondello P; Pitini V; Arrigo C; Derenzini E; Mian M
    Anticancer Res; 2014 Sep; 34(9):5121-5. PubMed ID: 25202102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers.
    Fossard G; Broussais F; Coelho I; Bailly S; Nicolas-Virelizier E; Toussaint E; Lancesseur C; Le Bras F; Willems E; Tchernonog E; Chalopin T; Delarue R; Gressin R; Chauchet A; Gyan E; Cartron G; Bonnet C; Haioun C; Damaj G; Gaulard P; Fornecker L; Ghesquières H; Tournilhac O; da Silva MG; Bouabdallah R; Salles G; Bachy E
    Ann Oncol; 2018 Mar; 29(3):715-723. PubMed ID: 29253087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).
    Ganjoo K; Hong F; Horning SJ; Gascoyne RD; Natkunam Y; Swinnen LJ; Habermann TM; Kahl BS; Advani RH
    Leuk Lymphoma; 2014 Apr; 55(4):768-72. PubMed ID: 23786456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.